Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers safety and immunogenicity

Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers : safety and immunogenicity

Copyright 2009 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 134(2010), 2 vom: 15. Feb., Seite 113-20
1. Verfasser: Salemi, S (VerfasserIn)
Weitere Verfasser: Picchianti-Diamanti, A, Germano, V, Donatelli, I, Di Martino, A, Facchini, M, Nisini, R, Biselli, R, Ferlito, C, Podestà, E, Cappella, A, Milanetti, F, Rossi, F, Amodeo, R, Tabacco, F, Di Rosa, R, Laganà, B, D Amelio, R
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2010
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Viral Antigens, Viral Antirheumatic Agents Immunoglobulin G Influenza Vaccines mehr... Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Infliximab B72HH48FLU Adalimumab FYS6T7F842 Etanercept OP401G7OJC
Beschreibung
Zusammenfassung:Copyright 2009 Elsevier Inc. All rights reserved.
Twenty-eight patients with low-moderate, stable rheumatoid arthritis (RA), under treatment with tumor necrosis factor (TNF) alpha blockers, were immunized at least once with non-adjuvanted trivalent influenza vaccine during three consecutive influenza seasons. Antibodies toward A influenza antigens significantly increased and reached protective levels, still detectable 6 months after vaccination, both in RA patients and healthy controls. Response to B antigen instead was only observed from the second year for healthy controls and in the third year for patients. No significant difference in disease activity and anti-nuclear antibodies was observed as a consequence of vaccine administration, whereas T regulatory cells showed a significant increase 30 days after immunization in RA patients. This study confirms safety of influenza vaccine administration in RA patients treated with TNFalpha blockers. The cohort follow-up revealed the overcoming of poor B vaccine antigen immunogenicity via repeated vaccinations. Finally, protective antibody response was still observed 6 months after vaccination
Beschreibung:Date Completed 02.03.2010
Date Revised 30.03.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2009.09.014